What is Robocath?
Founded in 2009 by Dr. Philippe Bencteux, Robocath specializes in the design, development, and commercialization of robotic systems for the treatment of cardiovascular diseases. Its flagship innovation, R-One, represents a significant advancement in robotic-assisted coronary angioplasty. By providing an open-architecture platform compatible with existing cath lab infrastructure, Robocath enables clinicians to perform revascularization procedures with heightened precision and reduced radiation exposure. The company's commitment to safety and efficacy is evidenced by successful pre-clinical trials and CE marking, positioning it as a critical player in the global medical technology market. With a dedicated team based in Rouen, France, Robocath is actively expanding its footprint across Europe and Africa, aiming to set new standards in vascular intervention.
How much funding has Robocath raised?
Robocath has raised a total of $56.3M across 3 funding rounds:
Series A
$7.6M
Series B
$5.3M
Series C
$43.4M
Series A (2017): $7.6M with participation from M Capital Advisors, Normandie Participations, GO Capital, Cardio Participation, and Groupe Credit Agricole
Series B (2019): $5.3M led by Supernova Invest, Go Capital, NCI, Normandie Participations, and M Capital
Series C (2020): $43.4M supported by TUS-Holdings, Zhejiang Silk Road Fund, Anaxago, CS Group, and MicroPort Scientific Corporation
Key Investors in Robocath
Supernova Invest
Supernova Invest empowers deeptech leaders by providing expertise and patient capital to support high-growth start-ups in Industrial Technologies, Digital, Healthcare, and Cleantech sectors.
Go Capital
A strategic investment firm focused on bridging advanced technology with international markets, particularly through the integration of Israeli innovation and global manufacturing ecosystems.
NCI
A major player in regional private equity, NCI provides expertise and equity to support the development and growth of SMEs and startups across various French regions.
What's next for Robocath?
With the support of its latest major strategic investment, Robocath is well-positioned to accelerate its international expansion and deepen its R&D capabilities. The strategic focus moving forward involves scaling the deployment of the R-One system and exploring the remote treatment of vascular emergencies, a frontier that could redefine the standard of care for patients in underserved regions. By leveraging its open-architecture technology, the company intends to foster further integration with market-leading devices, ensuring that its robotic solutions remain at the forefront of the evolving medical robotics industry. As Robocath continues to refine its clinical pathways, the focus remains on achieving global leadership in vascular robotics and delivering sustainable, high-precision outcomes for cardiovascular patients worldwide.
See full Robocath company page
